UP 284
Alternative Names: UP-284Latest Information Update: 28 Jun 2026
At a glance
- Originator Up Therapeutics
- Developer Johns Hopkins University; Tuskegee University; Up Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action ADRM1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Ovarian cancer; Prostate cancer; Triple negative breast cancer
- No development reported Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 25 Apr 2025 Pharmacodynamics data from preclinical trials in Triple-negative breast cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 13 Sep 2023 Discontinued - Preclinical for Multiple myeloma in USA (unspecified route) (UP Therapeutics pipeline, September 2023)